

Bioblast Pharma Ltd.
Form F-1/A
April 06, 2017

As filed with the Securities and Exchange Commission on April 6, 2017

Registration No. 333-216238

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Amendment No. 4

to

Form F-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Bioblast Pharma Ltd.

(Exact name of registrant as specified in its charter)

State of Israel	2834	Not Applicable
<i>(State or other jurisdiction of</i>	<i>(Primary Standard Industrial</i>	<i>(I.R.S. Employer</i>
<i>incorporation or organization)</i>	<i>Classification Code Number)</i>	<i>Identification Number)</i>

Mr. Fredric Price
Bioblast Pharma Ltd.
37 Dereh Menachem Begin St.,
15th Floor
Tel-Aviv 6522042 Israel

Tel: +972-72-240-9060
(Address, including zip code, and telephone number,

Zysman, Aharoni, Gayer and
Sullivan & Worcester LLP

1633 Broadway
New York, NY 10019

Tel: 212.660.5000
(Name, address, including zip code, and telephone

including area code, of registrant's principal executive offices) number, including area code, of agent for service)

Copies to:

Oded Har-Even, Esq.

Shy S. Baranov, Esq.

Robert V. Condon III, Esq.

Zysman, Aharoni, Gayer and

Sullivan & Worcester LLP

1633 Broadway

New York, NY 10019

Tel: 212.660.5000

Mor Limanovich, Adv.

David Huberman, Adv.

Zysman, Aharoni, Gayer & Co.

41-45 Rothschild Blvd.

Beit Zion

Tel-Aviv, Israel 65784

Tel: +972.3.795.5555

Rick A. Werner, Esq.

Haynes and Boone, LLP

**30 Rockefeller Plaza, 26th
Floor**

New York, NY 10112

Tel: 212.659.7300

Dr. Zvi Gabbay, Adv.

**Barnea & Co.
HaRakevet St. 58
Tel Aviv, Israel**

6777016

Tel: +972.3.640.0600

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date hereof.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

EXPLANATORY NOTE

This Amendment is filed solely to file Exhibit 5.2 and to reflect such filing in the Index to Exhibits. No change is made to the preliminary prospectus constituting Part I of the Registration Statement or Items 6, 7, or 9 of Part II of the Registration Statement.

Item 8. Exhibits and Financial Statement Schedules

Exhibits:

Exhibit

Number Exhibit Description

- 1.1* Form of Underwriting Agreement by and among Bioblast Pharma Ltd. and the underwriters named therein.
- 3.1* Amended and Restated Articles of Association of the Company, filed as Exhibit 3.2 to Form F-1/A filed on July 8, 2014 (File No. 333-193824), and incorporated herein by reference.
- 4.1* Form of Series A Warrant.
- 4.2* Form of Pre-Funded Series B Warrant.
- 4.3* Form of Ordinary Share Purchase Warrant issued to investors on March 22, 2016, filed as Exhibit 4.1 to Form 6-K filed on March 18, 2016 (File No. 001-36578), and incorporated herein by reference.
- 5.1* Opinion of Zysman, Aharoni, Gayer & Co., Israeli counsel to Bioblast Pharma Ltd., as to the validity of the Ordinary Shares being offered (including consent).
- 5.2 Opinion of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP, U.S. counsel to Bioblast Pharma Ltd.
- 10.1* Bioblast Pharma Ltd. 2013 Incentive Option Plan, as amended, filed as Exhibit 4.1 to Form 20-F filed on March 29, 2016 (File No. 001-36578), and incorporated herein by reference.
- 10.2* Bioblast Pharma Ltd. Compensation Policy for Company Office Holders, included in Exhibit 99.1 to Form 6-K filed on March 31, 2015 (File No. 001-36578), and incorporated herein by reference.
- 10.3* Form of Indemnification Agreement, filed as Exhibit 10.4 to Form F-1/A filed on April 8, 2014 (File No. 333-193824) and incorporated herein by reference.
- 23.1* Consent of Kost Forer Gabbay & Kasierer (a Member of EY Global).
- 23.2* Consent of Zysman, Aharoni, Gayer & Co. (included in Exhibit 5.1).
- 23.3 Consent of Zysman, Aharoni, Gayer and Sullivan & Worcester LLP (included in Exhibit 5.2).
- 24.1* Power of Attorney (included on the signature page of the Registration Statement).
- 101* The following materials from our registration statement on Form F-1 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Changes in Shareholders' Equity, (iv) the Consolidated Statements of Cash Flows and (v) the Consolidated Notes to Financial Statements, tagged as blocks of text and in detail.

*Previously filed.

Financial Statement Schedules:

All financial statement schedules have been omitted because either they are not required, are not applicable or the information required therein is otherwise set forth in our financial statements and related notes thereto.

SIGNATURES

Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Tel Aviv, Israel on April 6, 2017.

BIOBLAST PHARMA LTD.

By: /s/ Fredric Price
 Fredric Price,
 Executive Chairman of the Board of Directors and Chief
 Executive Officer

Pursuant to the requirements of the Securities Act, this registration statement on Form F-1 has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Fredric Price Fredric Price	Executive Chairman of the Board of Directors, Chief Executive Officer	April 6, 2017
/s/ Chaime Orlev Chaime Orlev	Chief Financial Officer, Vice President of Finance and Administration	April 6, 2017
/s/ * Michael Burshtine	Director	April 6, 2017
/s/ * Thomas I.H. Dubin	Director	April 6, 2017
/s/ * Colin Foster	Director	April 6, 2017
/s/ * Robert Friedman	Director	April 6, 2017
/s/ * Marlene Haffner	Director	April 6, 2017

/s/ * Director April 6, 2017
Dr. Dalia Megiddo

/s/ * Director April 6, 2017
Ran Nussbaum

/s/ * Director April 6, 2017
Dr. Ralf Roskamp

*By: /s/ Fredric Price
Fredric Price
Attorney-in-fact

SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

Pursuant to the Securities Act, as amended, the undersigned, Zysman, Aharoni, Gayer and Sullivan & Worcester LLP, the duly authorized representative in the United States of Bioblast Pharma Ltd. has signed this registration statement on April 6, 2017.

/s/ ZYSMAN, AHARONI, GAYER AND
SULLIVAN & WORCESTER LLP